Document:

<PAGE>

                                                                   EXHIBIT 10.23

                                LICENSE AGREEMENT

This License Agreement ("Agreement"), is made and entered into this 24 day of
June, 2002 ("Effective Date"), by and between

DADE BEHRING MARBURG GmbH, a German corporation having its principal place of
business at Emil-von-Behring-Stra(beta)e 76 , 35041 Marburg, Germany
(hereinafter called "DBM")

and

ILLUMINA INC., a U. S. corporation, having its principal place of business at
9885 Towne Centre Drive, San Diego, CA 92121-1975, USA (hereinafter called
"Illumina").

WHEREAS, DBM is the owner of United States Patent No. [*] and its foreign
counterparts; and

WHEREAS, ILLUMINA desires to obtain a worldwide, non-exclusive license to such
patents and patent applications.

NOW, THEREFORE, upon the mutual covenants contained herein and for other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:

ARTICLE I - DEFINITIONS

         1.1      Wherever used in this Agreement (in singular or plural form),
the terms and phrases set forth below shall have the following meanings:

----------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                                                    Page 1 of 17

<PAGE>

               (a) The term "Party" shall mean either DBM or Illumina, and the
         term "Parties" shall mean both DBM and Illumina.

               (b) The term "Affiliate(s)" shall mean (1) any corporation owning
         or directly or indirectly controlling at least 50% of the stock
         normally entitled to vote for election of directors of a Party, and (2)
         any corporation owned or directly or indirectly controlled by a (i)
         Party or (ii) an entity defined in subsection (b)(1) above, through
         ownership of at least 50% of the stock normally entitled to vote for
         election of directors; provided, however, in the circumstance where the
         country of incorporation of such owned or controlled corporation
         requires that maximum foreign ownership be less than 50%, the maximum
         permitted percentage of foreign ownership shall be substituted in this
         paragraph for 50%.

               (c) The term "Effective Date" shall mean the date set forth in
         the first paragraph of this Agreement.

               (d) The term "Licensed Patent(s)" shall mean those patents and
         patent applications which are listed in Exhibit A as well as any
         reexamination certificate, reissue, substitution, renewal, extension,
         addition, utility model or other patent right, U.S. or foreign, which
         has now issued or in the future may issue from any continuation,
         continuation in part or divisional application of such patents and
         patent applications.

               (e) The term "Licensed Product(s)" shall mean any human vitro
         diagnostic testing product and any other product whose manufacture,
         use, or sale would, but for the license granted under this Agreement,
         infringe any claim of a Licensed Patent which claim has not been held
         unpatentable, invalid or unenforceable by a decision of a competent
         tribunal from which no appeal has or can be taken or which claim has
         not been admitted by the patentee to be invalid or unenforceable.

                                                                    Page 2 of 17

<PAGE>

               (f) The term "Licensed Services" shall mean any services
         performed by using Licensed Products and any services the performance
         of which would in the absence of the license granted herein infringe
         any claim of a Licensed Patent which claim has not been held
         unpatentable, invalid or unenforceable by a decision of a competent
         tribunal from which no appeal has or can be taken, or which claim has
         not been admitted by the patentee to be invalid or unenforceable.

               (g) The term "Net Sales" shall mean the gross sales value of
         Licensed Products billed by Illumina and its Affiliates to third party
         customers less taxes, tariffs and value added taxes (VAT) as stated on
         the invoice and less 10 % (ten percent) as an average reasonable factor
         for all deductible costs attributable to such sales.

         These deductible costs included in such factor comprise: customs and
         cash discounts, trade discounts or quantity discounts; allowances or
         credits to customers on account of settlement of complaints; returns or
         retroactive price reductions, duties imposed upon the Licensed Products
         (except taxes, tariffs and VAT as hereinabove mentioned), costs for
         packaging, freight outwards or transportation insurance, and in the
         event that the Licensed Products are sold at an increased price to
         recover the costs of supplying a customer with an instrument system
         under a reagent rental plan, a reagent agreement plan or other
         successor or similar plan, the portion attributable to such costs
         recovery.

               (h) The term "sale" or "sold" shall mean shall mean to sell,
         hire, let, rent, lease or otherwise dispose of to a third party not
         being an Affiliate for monetary or other valuable consideration .

               (i) The term "Net Service Revenues " shall mean actual billings
         by Illumina or its Affiliates for the performance of Licensed Services
         less taxes imposed

                                                                    Page 3 of 17

<PAGE>

         upon the Licensed Services as stated on the billings and less
         allowances or credits to customers on account of settlement of
         complaints.

ARTICLE II - LICENSE GRANT

         2.1      Upon the terms and conditions set forth in this Agreement, DBM
grants to Illumina and its Affiliates a worldwide, non-exclusive license
(without the right to sublicense) under the Licensed Patents (i) to make, to
have made, to use, to have used, to import, to have imported, to offer to sell,
to have offered to sell, and to sell and to have sold Licensed Products and to
pass on to direct and indirect purchasers of Licensed Products the right to use
such purchased Licensed Products and (ii) to perform Licensed Services.

         2.2      Illumina agrees to apply the patent marking notice specified
by law of any country where a Licensed Patent is issued or pending and where
Licensed Products are made, used or sold, in accordance with the applicable
patent law of that country.

ARTICLE III - ROYALTY

         3.1      In consideration of the license granted hereunder, Illumina
shall pay to DBM: (1) a lumpsum of US $[*] ([*] and no/100 US dollars) payable
within sixty (60) days after the execution of this Agreement and (2) a running
royalty of [*] percent of the Net Sales of Licensed Products and (3) a running
royalty of [*] percent of Net Service Revenues.

         3.2      Net Service Revenues from Licensed Services and Net Sales from
the sale of Licensed Product between Illumina and its Affiliates shall not be
subject to royalty, but royalty shall be due upon performance of Licensed
Service for or sale of Licensed Product to any person or entity who is not an
Affiliate.

----------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                                                    Page 4 of 17

<PAGE>

ARTICLE IV - ROYALTY REPORT AND REMITTANCE

         4.1      Illumina is obliged to transmit to DBM

              (a) not later than sixty (60) days after the Effective Date of
              this Agreement,

                           (i) a written report showing the quantities of
                  Licensed Products sold and the Licensed Services performed by
                  Illumina or its Affiliates up to the Effective Date and the
                  corresponding Net Sales and Net Service Revenues, and

                           (ii) the royalties due in accordance with Section
                  3.1; and

              (b) within sixty (60) days from the end of each calender half-year
              periods of January 1 through June 30 and July 1 through
              December 31,

                           (i) a written report showing the quantities of
                  Licensed Products sold and Licensed Services performed by
                  Illumina or its Affiliates during the preceding half-year
                  period and the corresponding Net Sales and Net Service
                  Revenues, and

                           (ii) the royalties due in accordance with Section
                  3.1.

If there were no royalty bearing manufacture or sales of Licensed Products or
performance of Licensed Services, Illumina has to report so to DBM within said
term. Each such written report or the nil returns shall be sent to the following
address:

         Dade Behring Marburg GmbH
         Patents and Licenses Department
         Emil-von-Behring-Stra(beta)e 76
         35041 Marburg/Federal Republic of Germany

         4.2      The amount of royalty due has to be remitted in EURO and
within said term of paragraph 4.1 above to the following account of DBM, by
SWIFT-transfer:

                                                                    Page 5 of 17

<PAGE>

         Dresdner Bank AG, Frankfurt/Main-Hochst
         Account No. 770 491 400, BLZ: 500 800 00,
         SWIFT-Code DRESDEFF 500.

The obligation to pay shall only be fulfilled on the day on which said amount is
credited to the aforesaid account.

         4.3      For the conversion of US dollar into EURO the official spot
selling rate as stipulated by the Wall Street Journal on the business day
immediately preceding the business day on which such royalties were transmitted
to the bank account designated by DBM shall apply. For the conversion of
payments accrued in currencies other than US dollar into EURO the amount of said
payment shall be calculated first in US dollar at the spot-purchasing rate in
accordance with the afore-said procedure and the amount so obtained shall then
be converted into EURO applying the spot selling rate as provided above. If any
payment is delayed, the spot selling rate valid on the last business day of the
corresponding term of payment is to be used.

         4.4      On payments in arrears Illumina shall pay interest at the
rate:

               1-month-EURO-LIBOR plus 4 percentage points

Any losses suffered by DBM in terms of less favourable exchange rates as a
result of such a delayed payment have to be refunded by Illumina to DBM by
applying the modalities of accounting according to the above Section 4.3.

                                                                    Page 6 of 17

<PAGE>

ARTICLE V - BOOKKEEPING

         5.1      Illumina shall keep and, if applicable, have its Affiliates
keep correct and complete records of account as to the Licensed Products sold
and the Licensed Services performed, containing all information required for the
computation and verification of the Net Sales, Net Service Revenues and of the
royalties to be paid under this Agreement.

         5.2      During the term of this Agreement and within a period of two
(2) years after its termination DBM shall have the right to have such records of
account inspected and examined during ordinary business hours through an
independent certified public accountant reasonably acceptable to Illumina.
Illumina shall not need to maintain such records available for audit more than
three (3) years beyond the date of any given royalty report required under
section 4.1 unless such reports are matter of an ongoing dispute between the
Parties. On the request of Illumina the inspection and examination of the
records of account can also be done by the independent certified public
accountant who usually performs the inspection and examination of Illumina's
records of account. The costs for such inspection and examination shall be borne
by DBM; if the license account should be not in order by greater of five percent
(5%) of the amount of the royalties that should have been paid or ten thousand
($10,000) US dollars, the cost shall be borne by Illumina. The provision of this
Article V shall survive for two (2) years after termination of this Agreement or
until the end of an ongoing dispute between the Parties whichever date is later.

ARTICLE VI - TAXES

         6.1      All taxes imposed on payments made by Illumina to DBM
according to this Agreement outside the Federal Republic of Germany are to be
borne by DBM up to the tax rate laid down by the double taxation agreement
consisting between the Federal Republic of Germany and the United States of
America. Illumina is allowed to deduct the withholding tax, if any, from said
payments and has promptly to provide DBM with the appropriate tax receipts for
the taxes to be borne by DBM. Illumina is obliged to

                                                                    Page 7 of 17

<PAGE>

assist DBM in obtaining the limited tax rate according to the double tax treaty
by means of a tax exemption procedure or a tax reimbursement procedure.

         6.2      All other taxes, fees, payments or the like required by the
law of any country as a result of the use, manufacture or sale of a Licensed
Product or the performance of Licensed Services including, but not limited to,
any sales or value added taxes shall be the sole responsibility of and shall be
paid by Illumina.

ARTICLE VII - WARRANTIES AND DISCLAIMERS

         7.1      DBM warrants that it has the authority to grant the license
granted hereinabove and that such grant does not conflict with any of its legal
obligations.

         7.2      Other than as expressly provided in this Agreement, nothing in
this Agreement shall be construed as:

                        (a) a warranty or representation by DBM as to the
                  validity, enforceability or scope of any of the Licensed
                  Patents;

                        (b) a warranty or representation that anything made,
                  used, performed, sold, or otherwise disposed of under the
                  license granted in this Agreement is or will be free from
                  infringement of patents other than the Licensed Patents;

                        (c) an obligation to bring or prosecute actions or suits
                  against third parties for infringement of Licensed Patents;

                        (d) except as expressly set forth herein, conferring the
                  right to use in advertising, publicity or otherwise trademark,
                  trade name or names or any contraction, abbreviation,
                  simulation or adaptation thereof, of DBM;

                        (e) conferring by implication, estoppel or otherwise a
                  license, right or immunity under any patents or patent
                  applications of DBM or of its Affiliates

                                                                    Page 8 of 17

<PAGE>

              or any patents or patent applications which DBM or its Affiliates
              has the power to license other than the Licensed Patents;

                    (f) an obligation to furnish know-how not provided in the
              Licensed Patents; or

                    (g) creating any agency, partnership, joint venture or
              similar relationship between DBM and Illumina.

         7.3      Illumina shall hold harmless and indemnify DBM from and
against all claims, demands, actions, liabilities and damages ("Claims") made
by, or awarded to, any person or entity and any costs and expenses thereof
arising from, or connected with, the manufacture, use, sale or other disposal of
the Licensed Products or the performance of Licensed Services or the provision
or use of the Licensed Patents or otherwise arising out of the grant of any
rights hereunder or the provision of any information in connection herewith, but
only to the extent such Claims do not result from the gross negligence or
intentional misconduct of DBM. In the event that DBM seeks indemnification under
the Section 7.3, it shall inform Illumina as soon as reasonably practicable
after it becomes aware of any Claim, shall permit Illumina to assume direction
and control of the defense of the Claim (including the right to settle the Claim
solely for monetary consideration) and shall cooperate as reasonably requested
in the defense of the Claim.

         7.4      DBM shall not be liable to Illumina, its Affiliates or any
direct or indirect customer of Illumina for any damage or loss of whatsoever
nature sustained by Illumina, its Affiliates or any direct or indirect customer
of Illumina or for third party's claims against Illumina, its Affiliates or
any direct or indirect customer of Illumina arising out of or in connection with
or related to the performance of this Agreement, except to the extent such
damages or losses arise out of or are related to the gross negligence or
intentional misconduct by DBM.

                                                                    Page 9 of 17

<PAGE>

         7.5      NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER
PARTY ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES,
INCLUDING WITHOUT LIMITATION LOST PROFITS, IN CONNECTION WITH THE AGREEMENT OR
ANY LICENSE GRANTED HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF
SUCH DAMAGES.

         7.6      Nothing in this Agreement shall be construed as a warranty or
representation by DBM as to the Licensed Products and Licensed Services, their
quality, their technical properties and commercial viability or any other
aspects thereof.

         7.7      DBM MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OF LICENSED PRODUCTS AND/OR LICENSED
SERVICES.

         7.8      The provision under this Article VII shall survive the
termination of this Agreement.

ARTICLE VIII - SEVERABILITY

         8.1      Should one or several provision(s) of this Agreement be or
become invalid, then the Parties hereto shall substitute such invalid provisions
by valid ones, which in their economic effect come so close to the invalid
provisions that it can be reasonably assumed that the Parties would also have
concluded this Agreement with this new provision. In case such a provision
cannot be found, the invalidity of one or several provisions of this Agreement
shall not affect the validity of the Agreement as a whole, unless the invalid
provisions are of such essential importance for this Agreement that it is to be
reasonably assumed that the Parties would not have concluded this Agreement
without the invalid provisions.

                                                                   Page 10 of 17

<PAGE>

ARTICLE IX - GOVERNING LAW - VENUE

         9.1      This Agreement shall be interpreted and construed, and the
legal relations created herein shall be determined, in accordance with the laws
of the Federal Republic of Germany. Venue for juridical proceedings shall be
Dusseldorf, Germany

ARTICLE X - ASSIGNMENT

         10.1     This Agreement shall be binding and inure to the benefit of
the Parties and to their successors and permitted assigns. Either DBM or
Illumina may, at its sole discretion, assign this Agreement or transfer all of
its rights under this Agreement to any Affiliate, or cause any Affiliate to have
the benefit of all of its rights hereunder. Either Party may assign or transfer
all of its rights under this Agreement as a part of the sale of the business to
which it relates. In the case of an assignment, the performance of the assignee
will be guaranteed by the assignor. Neither this Agreement nor any interest
herein is otherwise assignable or transferable by Illumina without prior written
approval of DBM. This Agreement is fully assignable by DBM.

ARTICLE XI -  UNLICENSED COMPETITORS - ASSISTANCE OF ILLUMINA

         11.1     Illumina shall inform DBM of third parties which to the best
of Illumina' knowledge infringe Licensed Patents and, upon request of DBM, shall
reasonably assist DBM, e. g. by supplying information and evidences, in
enforcing DBM to stop infringement and unlicensed competition either by granting
licenses at reasonable conditions or by taking legal action or otherwise. It is
understood, however, that it is at the sole discretion of DBM whether and what
action shall be taken to avoid unlicensed competition.

                                                                   Page 11 of 17
<PAGE>

ARTICLE XII - FORCE MAJEURE

         12.1     All cases of force majeure which shall include but not be
restricted to fire, flood, earthquake, explosion, riot, strike, lock-out, acts
of terrorism, war and regulations of any governmental or local authority shall,
for the duration of and to the extent of the effects caused by such incidents,
release the Parties from the performance of their contractual obligations,
except the obligation to pay royalty as provided for under Article III and
Article IV.

         12.2     Either Party shall notify the other Party without delay of any
such incident occurring and the Parties shall discuss the effects of such
incidents on this Agreement and the measures to be taken.

         12.3     Either Party shall use its best efforts to reasonably avoid or
restrict any detrimental effects. The Parties shall as soon as reasonably
possible, resume performance of their obligations provided, however, that
neither Party shall, in order to prevent or terminate a strike or lock-out, take
the measures which it does not deem reasonable.

ARTICLE XIII - CONFIDENTIALITY

         13.1     Both Parties undertake to keep secret any and all information
received under this Agreement and to obligate also its employees to the same
extent and to the extent legally permissible, even for the time after their
employment. This obligation shall not apply, however, to such information for
which the receiving Party proves that it was already known to it prior to its
receipt or that it will become known by publication or otherwise become lawfully
available or that it is required to be disclosed under any applicable law,
regulations or governmental order. The provision of this Article XIII shall
survive the termination of this Agreement for five years.

                                                                   Page 12 of 17
<PAGE>

ARTICLE XIV - DURATION - TERMINATION

         14.1     This Agreement shall come into force and effect after it has
been executed, i.e. signed by both Parties.

Unless sooner terminated, it shall continue to be in force and effect for each
country covered under this Agreement until expiration of the Licensed Patents in
such country. The expiration of a Licensed Patent in any given country shall not
affect the effectiveness or non-effectiveness of this Agreement in any other
country.

         14.2     If a Licensed Patent in a country will be revoked, withdrawn
or becomes otherwise abandoned by a final decision which cannot be appealed, the
obligation to pay royalty for the license under such Licensed Patent for such
country shall cease effective as of the date of such final decision. Royalties
which have been paid under such Licensed Patent before such final decision will
not be returned, neither totally nor in part; and DBM has no obligation
whatsoever to make compensation for the royalty payments made before the date of
such final decision.

         14.3     Illumina shall have the right to terminate this Agreement by
giving six (6) months prior written notice to DBM.

         14.4     DBM shall have the right to terminate this Agreement
immediately by giving six (6) months prior written notice if for reasons other
than Force Majeure during a period of twenty four (24) months or more no
Licensed Products have been sold and no Licensed Services performed and no
running royalty payment was due and has been made, or if Illumina suspends
payment of its debts or enters into or becomes subject to corporate
rehabilitation procedures, liquidation, dissolution or bankruptcy proceedings
(that are not dismissed within sixty (60) days of the initiation of such
proceedings).

                                                                   Page 13 of 17
<PAGE>

         14.5     Each Party shall have the right to terminate this Agreement
immediately by written notice to the other Party if said other Party commits a
material breach of the terms of this Agreement and fails to correct such
material breach within sixty (60) days following receipt of written notice of
such breach pursuant to Section 15.4.

         14.6     Termination of this Agreement for any reason including
termination due to lapse of time shall not relieve Illumina of its obligation to
make payments of any royalty due under this Agreement prior to the effective
date of such termination or to provide to DBM any report with respect thereto.
This Section 14.6 shall survive termination of this Agreement.

ARTICLE XV - MISCELLANEOUS

         15.1     The Parties agree to execute, acknowledge and deliver all such
further instruments, and to do all such other acts, as may be necessary or
appropriate in order to carry out the intent and purposes of this Agreement.

         15.2     This Agreement including Exhibit A constitutes the entire
agreement and understanding between the Parties and supersedes any prior
agreements and understandings with respect to the Licensed Products and Licensed
Services.

         15.3     A waiver of any breach of any provision of this Agreement
shall not be construed as a continuing waiver of other breaches of the same or
other provisions of this Agreement.

         15.4     Notices required under this Agreement shall be in writing and
shall for all purposes be deemed to be fully given and received if sent by
registered mail, postage prepaid, return receipt requested, to the respective
Party at the following addresses (or at such other address as either Party may
hereinafter designate in writing):

                                                                   Page 14 of 17
<PAGE>

          If to DBM:
          Dade Behring Marburg GmbH
          Patents and Licenses
          Emil-von-Behring-Str. 76
          35041 Marburg
          Federal Republic of Germany

          If  to Illumina :
          Illumina Inc.
          Chief Executive Officer
          9885 Towne Centre Drive
          San Diego, CA 92121-1975

         15.5     The Parties are independent contractors and nothing contained
herein shall constitute either Party as the agent of the other or shall make the
Parties partners for any purpose. Neither Party shall, without the consent of
the other Party, take any action that purports to be the action of, or to be
binding upon, the other Party.

                                                                   Page 15 of 17
<PAGE>

IN WITNESS WHEREOF, the Parties have affixed their signatures on the dates
indicated below to two (2) duplicate originals, each of which shall be
considered an original.

         DADE BEHRING MARBURG GMBH

By:      ./s/ N. MADRY         /s/ B. AUERBACH

         Dr. N. Madry          Dr. B. Auerbach

Title:   Vice President &      Director
         Managing Director     Patents & Licenses

Date:    July 1, 2002

         ILLUMINA INC.

By:      /s/ JOHN R. STUELPNAGEL

Title:   Sr. Vice President, Operations

Date:    July 2, 2002

                                                                   Page 16 of 17
<PAGE>

                                    EXHIBIT A

<TABLE>
<CAPTION>
         COUNTRY          APP. NO.   FILE DATE   PATENT NO.   GRANT DATE
------------------------  --------  -----------  ----------   -----------
<S>                       <C>       <C>          <C>          <C>
Canada                      [*]     24-Aug-1989      [*]      28-Sep-1999
Germany                     [*]     24-Aug-1999      [*]      05-Oct-1994
France                      [*]     24-Aug-1989      [*]      05-Oct-1994
Great Britain               [*]     24-Aug-1989      [*]      05-Oct-1994
United States of America    [*]     25-Aug-1988      [*]      09-Feb-1993
United States of America    [*]     10-Mar-1995      [*]      14-May-1996
</TABLE>

----------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                                                   Page 17 of 17<PAGE>

                                                                   EXHIBIT 10.24

Confidential and Proprietary

                         NON-EXCLUSIVE LICENSE AGREEMENT

         THIS NON-EXCLUSIVE LICENSE AGREEMENT (the "Agreement"), made on this
24th day of January 2002, is by and between Illumina, Inc., a Delaware
corporation having its principal place of business at 9885 Towne Centre Drive,
San Diego, CA 92121-1975 ("Illumina"), and Amersham Biosciences Corp, formerly
Amersham Pharmacia Biotech Inc., a Delaware corporation having its principal
place of business at 800 Centennial Avenue, Piscataway, New Jersey 08855-1327
("Amersham"). Illumina and Amersham are hereinafter collectively referred to as
"Parties", or individually a "Party".

                               W-I-T-N-E-S-S-E-T-H

         WHEREAS, Illumina is a company engaged in developing an array confocal
scanning instrument for use with its existing BeadArray(TM) technology; and

         WHEREAS, Amersham owns or controls certain confocal scanning
instrumentation technology with potential application to Illumina's
BeadArray(TM) technology; and

         WHEREAS, Amersham desires to grant, and Illumina desires to acquire, on
the terms and conditions set forth in this Agreement, a license to intellectual
property relating to the use of Amersham's confocal scanning instrumentation
technology in the development and commercialization of an instrument utilizing
Illumina's BeadArray(TM) technology;

         NOW THEREFORE, in consideration of the above premises and the mutual
covenants herein contained and other good and sufficient consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows.

SECTION 1. DEFINITIONS

         In this Agreement and in the licenses referred to herein, unless the
context otherwise requires, the following definitions shall apply:

         1.1      "AFFILIATE" means any corporation or other business entity
controlled by, controlling, or under common control with a party, with "control"
meaning direct or indirect beneficial ownership of more than fifty percent (50%)
of the voting stock of, or more than a fifty percent (50%) interest in the
income of, or the right to receive more than fifty percent (50%) of the
distributed profits of such corporation or other business entity, or such other
relationship as, in fact, constitutes actual control.

         1.2      "AMERSHAM PATENTS" means (i) all United States and foreign
patents and patent applications owned by Amersham or its Affiliates related to
confocal scanning instrumentation technology issued on or before the Effective
Date, known as the "Kain Patents" listed in Appendix A, attached hereto and
incorporated by reference, including all divisions, continuations,
continuations-in-part, re-issues, re-examinations and substitutes thereof. For
the avoidance of doubt, U.S. Patent No. 5,091,652 licensed by Amersham from the
University of California is not included in the Amersham Patents under this
Agreement.

         1.3      "EFFECTIVE DATE" means the date first above written, which
shall be the date of execution of this Agreement.

         1.4      "FIELD OF USE" means the internal development of the
Instrument solely by Illumina and its Affiliates, as well as the manufacture and
sale of the Instrument solely by Illumina, its Affiliates, and its authorized
subcontract manufacturers or distributors.

                                   page 1 of 8
<PAGE>

Confidential and Proprietary

         1.5      "ILLUMINA BEADARRAY(TM) TECHNOLOGY" means Illumina's
technology covered by U.S. Patent Nos. 6,023,540, 6,210,910, 6,266,459 and
6,327,410, which combines a patterned substrate and specially prepared beads or
cells that self-assemble into an array for use in chemical or biochemical
detection.

         1.6      "INSTRUMENT(S)" means Illumina's array confocal scanning
instrument covered by a Valid Claim and developed for the detection and imaging
of samples based on Illumina's BeadArray(TM) technologY.

         1.7      "VALID CLAIM" means a claim of an unexpired Amersham Patent
that has not been declared invalid by a court or administrative agency from
which no appeal is or can be taken, and which has not been disclaimed, denied or
admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise.

SECTION 2. GRANTS

         2.1      Grant of License to Amersham Patents. Amersham hereby grants
to Illumina and its Affiliates, who accept the same, a worldwide, non-exclusive,
non-assignable license to the Amersham Patents, solely in the Field of Use, to
make, have made, use, sell, have sold or import Instruments. The rights and
licenses granted hereunder may not be sublicensed by Illumina to third parties,
other than as necessary in connection with Illumina's activities in the Field of
Use.

SECTION 3. LICENSE FEE

         3.1      In consideration of the rights granted in Section 2 above,
Illumina shall pay to Amersham a non-refundable license fee in the amount of [*]
Dollars U.S. dollars (U.S. $[*]), payable within ninety (90) days of the
Effective Date. The license fee shall be paid by wire transfer to the bank
account specified by Amersham at the time the payment is to be made.

         3.2      Any amount not paid by Illumina when due will accrue interest
at the lesser of the rate of one and one-half percent (1.5%) per month or the
highest rate permissible by law from the due date until paid in full.

SECTION 4. ROYALTIES

         4.1      Illumina shall pay Amersham a recurring royalty of [*]Dollars
(US $[*]) for each Instrument sold by Illumina. Such royalties shall be payable
within thirty (30) days after the anniversary of the Effective Date.

         4.2      Notwithstanding the pendency of any infringement (or other)
claim or action by or against Illumina, Illumina shall have no right to
terminate or suspend (or escrow) payment of any amounts required to be paid to
Amersham pursuant to this Agreement.

SECTION 5. OBLIGATIONS

         5.1      Illumina shall advise Amersham promptly, and shall furnish
documentary proof which is reasonably acceptable to Amersham, upon its becoming
aware of substantial infringement by a third party or parties of an enforceable
intellectual property right included in the Amersham Patents. Upon receipt of
said written information, Amersham shall, at its sole discretion, take such
action as it deems appropriate to address such circumstances.

----------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                   page 2 of 8

<PAGE>

Confidential and Proprietary

         5.2      The Parties shall reasonably and mutually agree and identify
documentation or other information (e.g. laboratory notebooks and images) which
supports the conception and reduction to practice of the Amersham Patents and
which is reasonably required within the Field of Use, ("Patent Documentation and
Information"). The Parties shall mutually agree as to the form in which the
Patent Documentation and Information will be conveyed to Illumina, but in any
event, all Patent Documentation and Information shall be clearly marked as
"Confidential" or "Proprietary".

SECTION 6. INDEMNIFICATION

         6.1      Illumina shall defend, indemnify and hold harmless Amersham
and its directors, officers, shareholders, agents, consultants and employees
(the "Indemnitees") from and against any and all liability, loss, damages and
expenses (including reasonable attorneys' fees) as the result of claims,
demands, costs or judgments which may be made or instituted against Amersham
arising out of the use or sale by Illumina and/or its customers, Affiliates,
agents, consultants, and employees of any Instrument or the Amersham Patents in
a manner that infringes any intellectual property right of a third party.

         6.2      Amersham shall promptly notify Illumina of any claim by a
third party against Amersham related to Illumina's use or that of its customers,
Affiliates, agents consultants, or employees, of the Instrument, and/or Amersham
Patents as used with any Instrument and shall provide full details of the claim.
Illumina shall have its choice of representation and complete control and
discretion in any action for which it indemnifies Amersham. Amersham will
cooperate in the defense of any such claim and will not settle the same without
Illumina's written consent, unless Amersham releases Illumina from all of
Illumina's obligations under this Section 6 with respect to the claim.

SECTION 7. TERM AND TERMINATION

         7.1      Term. The term of this Agreement with respect to the Amersham
Patents shall be from the Effective Date and shall continue unless terminated
earlier as provided in Section 7.2 below. The term of the license granted
hereunder to the Amersham Patents shall commence on the Effective Date and shall
continue in perpetuity with respect to any Instrument sold prior to any such
termination of this Agreement.

         7.2      Termination. Notwithstanding Section 7.1 hereof, a Party may
at its sole option and upon giving written notice to the other Party,
immediately terminate this Agreement upon any one or more of the following
events occurring in relation to the other Party (the "Defaulting Party"):

                  (a)      if the Defaulting Party shall commit any material or
         substantial breach of any of its obligations herein or of any of the
         provisions of this Agreement, and such Defaulting Party shall fail
         within thirty (30) days of being notified thereof in writing by the
         aggrieved Party to take all reasonable and diligent steps to remedy
         such breach or default; or

                  (b)      the Defaulting Party makes a general assignment for
         the benefit of creditors, or if a petition in bankruptcy or under any
         insolvency law is filed by or against the Defaulting Party and such
         petition is not dismissed within sixty (60) days after it has been
         filed; or

         7.3      Surrender of Rights by Illumina. Illumina shall have the right
to surrender its rights under this Agreement at any time, for Illumina's
convenience, upon sixty (60) days' prior written notice to Amersham. In any
event, there shall be no refund to Illumina of any consideration paid hereunder.

                                   page 3 of 8

<PAGE>

Confidential and Proprietary

         7.4      Return of Patent Documentation and Information. In the event
this Agreement is terminated or Illumina surrenders its rights hereunder,
Illumina shall immediately return any and all copies of any Patent Documentation
and Information, except to the extent embodied in a shipped Instrument, and any
other confidential or proprietary information provided to it, in any form
whatsoever.

         7.5      Claims. In the event this Agreement is terminated by an
aggrieved Party in accordance with the foregoing provisions of either Sections
7.2 or 7.3, neither Party shall have any claim against the other for
compensation or indemnity of any kind as a consequence of such termination,
provided, however, that such termination shall not affect any of the obligations
hereunder having arisen prior to the effective date of termination.

         7.6      Limit of Liability. EXCEPT AS EXPRESSLY STATED HEREIN, IN NO
EVENT SHALL EITHER PARTY, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES OR
AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND,
INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS.

SECTION 8. SUCCESSORS AND ASSIGNS

         8.1      Successors. This Agreement, and each and every one of the
terms and conditions thereof, shall inure to the benefit of and be binding upon
the permitted successors and assignees of both Parties.

         8.2      Assignment. This Agreement and the license granted hereunder
shall not be assigned or sold or in any way transferred by Illumina, except as
expressly set forth in this Agreement, without the prior written consent of
Amersham provided, however, that Illumina may assign its rights under this
Agreement to the purchaser of the portion of its business to which the licenses
granted under this Agreement relate.

SECTION 9. CONFIDENTIALITY

         9.1      The Parties entered into a prior "Confidentiality Agreement"
effective on June 30, 1999, which remains in force and effect as of the
Effective Date.

         9.2      "Confidential Information" shall mean any confidential
technical data, trade secret, know-how or other confidential information
disclosed by any party hereunder in writing, orally, or by drawing or other
form. From and after the Effective Date, disclosures or delivery of Confidential
Information or material hereunder by any Party will be made in writing and will
be marked "CONFIDENTIAL" or "PROPRIETARY". Any such Confidential Information or
material in oral form will be confirmed in writing within thirty (30) days and
will also be marked "CONFIDENTIAL" or "PROPRIETARY".

         9.3      Such Confidential Information will be safeguarded by the
recipient in the same manner and with at least the same protection as such Party
maintains for its own confidential information (but in any event with reasonable
care) and will not be disclosed to third parties and will be made available only
to the receiving Party's Affiliates, and their employees or agents (including
attorneys) who need to know such information.

         9.4      These mutual obligations of confidentiality shall apply with
respect to each item of Confidential Information until five years after
disclosure of such item to the other Party, but the mutual obligations of
confidentiality will not apply to any information to the extent that such
information:

                  (a)      is or hereafter becomes part of the public domain
         through no action or inaction on the part of the recipient of the
         information which constitutes a default under this Section 9;

                                   page 4 of 8

<PAGE>

Confidential and Proprietary

                  (b)      was already known to the recipient as evidenced by
         prior written documents in its possession which were not furnished by
         the other Party;

                  (c)      is disclosed to the recipient by a third party who is
         not in default under any confidentiality obligation to the disclosing
         Party;

                  (d)      is required by law to be disclosed, including without
         limitation in connection with the registration or filing with, or
         approval or certification from, any governmental agency or body such as
         but not limited to the United States Food and Drug Administration
         provided that the information is not the inventive subject matter of an
         unpublished patent application and, provided further, that each Party
         undertakes its best efforts to maintain, to the maximum extent
         reasonably possible, the confidentiality of such information.

                  (e)      can be proven to have been independently developed by
         the recipient, without the aid, application or use in any way of
         information received by the recipient from the other Party to this
         Agreement.

         9.5      Upon the expiration or termination of this Agreement, or
surrender by Illumina of its rights hereunder, each Party shall immediately
return any and all copies of any Confidential Information or material provided
to it by the other Party, in any form whatsoever.

         9.6      Notwithstanding any provision of this Agreement to the
contrary, the provisions of this Section 9 shall survive any expiration or
termination of this Agreement.

SECTION 10. PUBLICITY

         10.1     A Party shall not, without prior review and written approval
by the other Party, issue any public announcement or press release relating to
the existence and/or subject matter of this Agreement. Not withstanding the
foregoing, the Parties will work together to issue a press release relating to
the existence of this Agreement. To the extent required under applicable law and
subject to a Party using commercially reasonable effort to obtain confidential
treatment of the terms of this Agreement to the maximum extent provided by law,
a Party shall have the right to disclose the existence and terms of this
Agreement in its filings to the SEC. In connection with any such disclosure in
its filings to the SEC, a Party shall provide written notice to the other Party
of its proposed disclosure in advance of any such disclosure and provide the
other Party with a reasonable opportunity to comment on such proposed
disclosure.

SECTION 11. REPRESENTATIONS, WARRANTIES AND DISCLAIMERS

         11.1     Amersham Warranties. Amersham makes the following warranties
and representations:

                  (a)      Amersham warrants that except as otherwise set forth
                           herein, to the best of its knowledge, it owns the
                           Amersham Patents free and clear of all liens,
                           encumbrances, and claims or demands of third parties.

         11.2     Illumina Warranties. Illumina makes the following warranties
and representations:

                  (a)      Illumina warrants that it will not practice or use
                           the Amersham Technology outside the Field of Use.

                                   page 5 of 8

<PAGE>

Confidential and Proprietary

         11.3     Mutual Warranties. Each Party hereby represents to the other
Party on the Effective Date and thereafter throughout the Term that, to the best
of its knowledge, this Agreement is a legal and valid obligation binding upon
its execution and enforceable in accordance with its terms and conditions. The
execution, delivery and performance of this Agreement by such Party have been
duly authorized by all necessary corporate action, and the person executing this
Agreement on behalf of such Party has been duly authorized to do so by all
requisite corporate actions and do not and will not (a) require any consent of
approval of its stockholders or any Third Party or (b) conflict with, or
constitute a material breach or violation of, any agreement, instrument,
understanding, oral or written, to which it is a party or by which it may be
bound, and any judgment of any court or governmental body applicable to such a
Party or (c) violate any law, decree, order, rule or regulation of any court,
governmental body or administrative or other agency having authority over it.

         11.4     Disclaimers. Except as expressly set forth in this Agreement,
nothing in this Agreement shall be construed as:

                  (a)      A warranty or representation by Amersham, either
                           express or implied, as to the validity,
                           enforceability, or scope of the claims of any
                           Amersham Patents; or

                  (b)      A warranty or representation by Amersham, either
                           express or implied, that any use under the license
                           granted in this Agreement, is or will be free from
                           infringement of patents or other rights of third
                           parties; or

                  (c)      A requirement that Amersham shall file any patent
                           application or secure any patent; or

                  (d)      An obligation of either Party to bring or prosecute
                           actions or suits against third parties for
                           infringement of any patents; or

                  (e)      Conferring any right to use in advertising,
                           publicity, or the like any name, tradename, or
                           trademark of either Party or any of its Affiliates;
                           or

                  (f)      Granting by implication, estoppel or otherwise any
                           licenses or rights under any patents and applications
                           for patents other than under the Amersham Patents.

SECTION 12 MISCELLANEOUS

         12.1     Governing Law and Jurisdiction. This Agreement shall be
governed by and construed in accordance with the law of the State of New Jersey.
The Parties agree that any legal action or proceeding under or with respect to
this Agreement may be brought in the courts of the State of New York and for the
purpose of any such legal action or proceeding the parties hereby submit to the
exclusive jurisdiction of such courts.

         12.2     Force Majeure. Any delays in or failure of performance by
either Party under this Agreement shall not be considered a breach thereof if
such delay or failure is occasioned by events beyond the reasonable control of
the Party affected ("Force Majeure"). Force Majeure in this context shall mean
and include but not be limited to acts of government or failure of government to
act where such action is required, acts of God, strikes or other concerted acts
of workmen including workmen of the Parties, fires, floods, explosions, riots,
civil disturbances, insurrections, earthquakes, wars rebellions, epidemics and
sabotage. The Party claiming Force Majeure shall notify the other Party of the
occurrence of the Force Majeure and shall use commercially reasonable efforts to
resolve the Force Majeure as soon as possible. The time for that Party's
performance shall be extended by the duration of the Force Majeure.

                                   page 6 of 8

<PAGE>

Confidential and Proprietary

         12.3     Severability; Waiver. Should any provision of this Agreement
be held by a court to be illegal or in conflict of any law, rule of law, statute
or regulation, (a) the validity of the remaining provisions will not be affected
thereby and (b) the illegal or unenforceable provision will be ineffective only
to the extent of such prohibition or invalidity, and the Parties shall
negotiate, in good faith, a new provision which will, as closely as possible,
carry out the intentions of the Parties provided for in the invalidated
provision. Any waiver by one Party of any rights arising from any breach by the
other Party will not be construed as a waiver of other breaches of the same or
other terms of this Agreement.

         12.4     Entirety of Agreement. This Agreement constitutes the entire
agreement between the Parties concerning the subject matter of this Agreement
and the rights granted thereunder. Any representations, warranties, terms,
conditions or covenants to amend, modify or otherwise alter this Agreement shall
be of no force and effect unless made in writing and signed by authorized
representatives of both Parties.

         12.5     Notices. Any notice to be given pursuant to this Agreement may
be delivered (i) personally to the place of business of the Party to whom it is
addressed, (ii) by prepaid, registered mail, return receipt requested, or (iii)
via Federal Express or other internationally-known and reputable overnight
delivery service, and addressed as follows:

                  (a)      If to ILLUMINA:
                           Illumina, Inc.
                           9885 Towne Centre Drive
                           San Diego, CA 92121-1975
                           Attention: Chief Patent Counsel

                  (b)      If to AMERSHAM:
                           Amersham Biosciences Corp
                           800 Centennial Avenue
                           Piscataway, New Jersey 08855-1327
                           Attention: General Counsel

         IN WITNESS WHEREOF, the Parties hereto have affixed their names and
seals by their duly authorized executive officers on the day and year first
above written.

ATTEST:                            ILLUMINA, INC

                                   By:  /s/ JOHN R. STUELPNAGEL

                                   Title:  Vice President, Business Development

ATTEST:                            AMERSHAM BIOSCIENCES CORP

                                   By: /s/ MARK L. LEWIS

                                   Title: Vice President, Genomics
                                   Business Development

                                   page 7 of 8

<PAGE>

Confidential and Proprietary

                                   APPENDIX A
                                       TO
                                LICENSE AGREEMENT

                    AMERSHAM PATENTS AND PATENT APPLICATIONS
                       (also known as the "Kain Patents")

                                     US [*]
                                     US [*]
                                     US [*]
                                     US [*]
                                     US [*]

  All divisions, continuations, continuation-in-part, reexaminations, reissues,
           renewals, and foreign counterparts of the above US patents.

----------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                   page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]